Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
PCRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.16 - $31.67
Previous CloseN/A
Volume54.84K
Average Volume (3M)906.49K
Market Cap
$1.15B
Enterprise Value$1.08B
Total Cash (Recent Filing)$26.13M
Total Debt (Recent Filing)$25.05M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Apr 30, 2025EPS Estimate
0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.20
Shares Outstanding46,276,240
10 Day Avg. Volume1,026,564
30 Day Avg. Volume906,487
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.59
Price to Cash Flow (P/CF)8.40
P/FCF Ratio8.20
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.54
Enterprise Value/Ebitda51.17
Forecast
1Y Price Target
$32.83Price Target Upside36.39% Upside
Rating ConsensusHold
Number of Analyst Covering8
---
Pacira Pharmaceuticals News
---
Bulls Say, Bears Say
Bulls Say
Patent ProtectionPCRX continues to add Exparel patents, effectively bolstering patent protection and creating hurdles for competitors.
Revenue PotentialExparel's current growth rate and new reimbursement opportunities suggest a higher revenue potential than the guided 3-9% year-over-year growth.
Strategic OutlookThe new strategic outlook aims for product revenues to grow by double-digit CAGR and a 5% gross-margin improvement.
Bears Say
Conservative Revenue GuidancePacira's first-time 2025 revenue guidance is seen as almost unreasonably conservative, considering the tailwinds from the NOPAIN Act and rapid commercial payer coverage.
Mixed Analyst CommentaryMixed KOL commentary from a Weill Cornell anesthesiologist raises questions about Exparel's value proposition.
---
Ownership Overview
2.79% Insiders
21.81% Mutual Funds
14.90% Other Institutional Investors
24.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PCRX FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was $11.16 and its highest was $31.67 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Pacira Pharmaceuticals’s market cap is $1.15B.
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is Apr 30, 2025 which is in 27 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Feb 27, 2025. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.835 by $0.075.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is 0.59.
How many shares outstanding does Pacira Pharmaceuticals have?
Pacira Pharmaceuticals has 46,276,240 shares outstanding.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of $0.91 in its last earnings report, beating expectations of $0.835. Following the earnings report the stock price went down -5.24%.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Currently, no hedge funds are holding shares in PCRX
---
Pacira Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$32.83 (36.39% Upside)
$32.83 (36.39% Upside)
Blogger Sentiment
Bullish
PCRX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 135.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.42%
12-Months-Change
Fundamentals
Return on Equity
-12.08%
Trailing 12-Months
Asset Growth
-1.33%
Trailing 12-Months
Company Description
Pacira Pharmaceuticals
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
---
PCRX Company Deck
---
PCRX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Pacira BioSciences reported strong financial performance for 2024 with record revenues and significant reimbursement progress for its flagship product, EXPAREL. However, the delayed uptake of the No Pain Act reimbursement and increased operating expenses are challenges that the company needs to navigate. The strategic acquisition of GQ Bio and expansion of commercial coverage are notable steps forward.Read More>---
PCRX Stock 12 Month Forecast
Average Price Target
$32.83
▲(36.39% Upside)
Technical Analysis
Opko Health
―
Innoviva
―
Iovance Biotherapeutics
―
Viridian Therapeutics
―
Syndax Pharmaceuticals
―
Best Analysts Covering PCRX
1 Year
1 Year Success Rate
14/40 ratings generated profit
1 Year Average Return
-4.06%
reiterated a buy rating last month
Copying Oren Livnat's trades and holding each position for 1 Year would result in 35.00% of your transactions generating a profit, with an average return of -4.06% per trade.
---